Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor

Anna Maria Orengo, Marina Fabbi, Loredana Miglietta, Cristian Andreani, Milena Bruzzone, Andrea Puppo, Paolo Cristoforoni, Maria Grazia Centurioni, Marina Gualco, Sandra Salvi, Simona Boccardo, Mauro Truini, Tiziana Piazza, Silvana Canevari, Delia Mezzanzanica, Silvano Ferrini

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.

Original languageEnglish
Pages (from-to)1116-1125
Number of pages10
JournalInternational Journal of Cancer
Volume129
Issue number5
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Interleukin-18
Biomarkers
Carcinoma
Ascitic Fluid
Serum
Interferons
Tumor Escape
Neoplasms
Histiocytes
Peritoneal Cavity
Endometrial Neoplasms

Keywords

  • biomarker
  • IL-18
  • immature precursor
  • ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. / Orengo, Anna Maria; Fabbi, Marina; Miglietta, Loredana; Andreani, Cristian; Bruzzone, Milena; Puppo, Andrea; Cristoforoni, Paolo; Centurioni, Maria Grazia; Gualco, Marina; Salvi, Sandra; Boccardo, Simona; Truini, Mauro; Piazza, Tiziana; Canevari, Silvana; Mezzanzanica, Delia; Ferrini, Silvano.

In: International Journal of Cancer, Vol. 129, No. 5, 01.09.2011, p. 1116-1125.

Research output: Contribution to journalArticle

Orengo, AM, Fabbi, M, Miglietta, L, Andreani, C, Bruzzone, M, Puppo, A, Cristoforoni, P, Centurioni, MG, Gualco, M, Salvi, S, Boccardo, S, Truini, M, Piazza, T, Canevari, S, Mezzanzanica, D & Ferrini, S 2011, 'Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor', International Journal of Cancer, vol. 129, no. 5, pp. 1116-1125. https://doi.org/10.1002/ijc.25757
Orengo, Anna Maria ; Fabbi, Marina ; Miglietta, Loredana ; Andreani, Cristian ; Bruzzone, Milena ; Puppo, Andrea ; Cristoforoni, Paolo ; Centurioni, Maria Grazia ; Gualco, Marina ; Salvi, Sandra ; Boccardo, Simona ; Truini, Mauro ; Piazza, Tiziana ; Canevari, Silvana ; Mezzanzanica, Delia ; Ferrini, Silvano. / Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. In: International Journal of Cancer. 2011 ; Vol. 129, No. 5. pp. 1116-1125.
@article{39ed694afd31494383026ff0fd28fd19,
title = "Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor",
abstract = "Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.",
keywords = "biomarker, IL-18, immature precursor, ovarian cancer",
author = "Orengo, {Anna Maria} and Marina Fabbi and Loredana Miglietta and Cristian Andreani and Milena Bruzzone and Andrea Puppo and Paolo Cristoforoni and Centurioni, {Maria Grazia} and Marina Gualco and Sandra Salvi and Simona Boccardo and Mauro Truini and Tiziana Piazza and Silvana Canevari and Delia Mezzanzanica and Silvano Ferrini",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/ijc.25757",
language = "English",
volume = "129",
pages = "1116--1125",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor

AU - Orengo, Anna Maria

AU - Fabbi, Marina

AU - Miglietta, Loredana

AU - Andreani, Cristian

AU - Bruzzone, Milena

AU - Puppo, Andrea

AU - Cristoforoni, Paolo

AU - Centurioni, Maria Grazia

AU - Gualco, Marina

AU - Salvi, Sandra

AU - Boccardo, Simona

AU - Truini, Mauro

AU - Piazza, Tiziana

AU - Canevari, Silvana

AU - Mezzanzanica, Delia

AU - Ferrini, Silvano

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.

AB - Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.

KW - biomarker

KW - IL-18

KW - immature precursor

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=79959690793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959690793&partnerID=8YFLogxK

U2 - 10.1002/ijc.25757

DO - 10.1002/ijc.25757

M3 - Article

VL - 129

SP - 1116

EP - 1125

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -